Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
Gain-of-function mutations in human androgen receptor (AR) are among the major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols, as well as for designing drugs that do not elicit adverse...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/16/5847 |
id |
doaj-32b39ff3ccc04873ae5f3c5cad1ac781 |
---|---|
record_format |
Article |
spelling |
doaj-32b39ff3ccc04873ae5f3c5cad1ac7812020-11-25T03:04:41ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-01215847584710.3390/ijms21165847Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer TherapiesOliver Snow0Nada Lallous1Martin Ester2Artem Cherkasov3School of Computing Science, Simon Fraser University, Burnaby, BC V5A 1S6, CanadaVancouver Prostate Centre, University of British Columbia, 2660 Oak St, Vancouver, BC V6H 3Z6, CanadaSchool of Computing Science, Simon Fraser University, Burnaby, BC V5A 1S6, CanadaVancouver Prostate Centre, University of British Columbia, 2660 Oak St, Vancouver, BC V6H 3Z6, CanadaGain-of-function mutations in human androgen receptor (AR) are among the major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols, as well as for designing drugs that do not elicit adverse responses. However, experimental characterization of these mutations is time consuming and costly; thus, predictive models are needed to anticipate resistant mutations and to guide the drug discovery process. In this work, we leverage experimental data collected on 68 AR mutants, either observed in the clinic or described in the literature, to train a deep neural network (DNN) that predicts the response of these mutants to currently used and experimental anti-androgens and testosterone. We demonstrate that the use of this DNN, with general 2D descriptors, provides a more accurate prediction of the biological outcome (inhibition, activation, no-response, mixed-response) in AR mutant-drug pairs compared to other machine learning approaches. Finally, the developed approach was used to make predictions of AR mutant response to the latest AR inhibitor darolutamide, which were then validated by in-vitro experiments.https://www.mdpi.com/1422-0067/21/16/5847prostate cancerandrogen receptordeep learningproteochemometrics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Oliver Snow Nada Lallous Martin Ester Artem Cherkasov |
spellingShingle |
Oliver Snow Nada Lallous Martin Ester Artem Cherkasov Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies International Journal of Molecular Sciences prostate cancer androgen receptor deep learning proteochemometrics |
author_facet |
Oliver Snow Nada Lallous Martin Ester Artem Cherkasov |
author_sort |
Oliver Snow |
title |
Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies |
title_short |
Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies |
title_full |
Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies |
title_fullStr |
Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies |
title_full_unstemmed |
Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies |
title_sort |
deep learning modeling of androgen receptor responses to prostate cancer therapies |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-08-01 |
description |
Gain-of-function mutations in human androgen receptor (AR) are among the major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols, as well as for designing drugs that do not elicit adverse responses. However, experimental characterization of these mutations is time consuming and costly; thus, predictive models are needed to anticipate resistant mutations and to guide the drug discovery process. In this work, we leverage experimental data collected on 68 AR mutants, either observed in the clinic or described in the literature, to train a deep neural network (DNN) that predicts the response of these mutants to currently used and experimental anti-androgens and testosterone. We demonstrate that the use of this DNN, with general 2D descriptors, provides a more accurate prediction of the biological outcome (inhibition, activation, no-response, mixed-response) in AR mutant-drug pairs compared to other machine learning approaches. Finally, the developed approach was used to make predictions of AR mutant response to the latest AR inhibitor darolutamide, which were then validated by in-vitro experiments. |
topic |
prostate cancer androgen receptor deep learning proteochemometrics |
url |
https://www.mdpi.com/1422-0067/21/16/5847 |
work_keys_str_mv |
AT oliversnow deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies AT nadalallous deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies AT martinester deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies AT artemcherkasov deeplearningmodelingofandrogenreceptorresponsestoprostatecancertherapies |
_version_ |
1724680263222427648 |